ESR1 and breast cancer: A retrospective study comprising 49 ER- and/or PR-positive patients with primary BC reported that reduced PTEN expression led to shorter relapse-free survival of TAM-treated patients, and loss of heterozygosity (LOH) of PTEN was significantly associated with shorter disease-free survival, cancer-specific survival, and OS of TAM-treated patients with BC [25].